Skip to main content
NCBI home page
The British Journal of General Practice logoLink to The British Journal of General Practice
. 1997 Mar;47(416):161–165.

Adequacy of hormone replacement therapy for osteoporosis prevention assessed by serum oestradiol measurement, and the degree of association with menopausal symptoms.

M Rodgers 1, J E Miller 1
PMCID: PMC1312923  PMID: 9167320

Abstract

BACKGROUND: Patients on hormone replacement therapy (HRT) for osteoporosis prevention rather than menopausal symptom control may be asymptomatic, despite inadequate replacement and low serum oestradiol (E2) levels. In the primary health care setting, therapeutic monitoring of HRT is not carried out routinely so that patients with serum E2 levels inadequate to protect bone may be missed. AIM: To determine the proportion of women on transdermal E2 preparations with serum E2 levels insufficient to protect bone and to assess the value of a questionnaire-derived menopausal symptom score (MSS) for detecting these patients. METHOD: A cross-sectional analysis of 45 patients aged 35-70 years using transdermal E2 preparations obtained from a computer register of 14500 patients in a suburban practice. One blood sample was obtained from each patient at the time the MSS questionnaire was completed. Serum E2 concentration was measured using a fluoroimmunoassay and compared with the MSS. Levels below 150 pmol/l were considered to be insufficient to protect bone. The diagnostic accuracy of the MSS in screening for levels below 150 pmol/l was determined using receiver operating characteristic (ROC) curve analysis. RESULTS: The median (95% CI) serum E2 was 147 pmol/l (126-198 pmol/l) and levels were below 150 pmol/l in 24 out of 45 patients. There was no difference in the MSS (median, 95% CI) between those with serum E2 < 150 pmol/l (8.5, 5.0-17) and > or = 150 pmol/l (9.0, 5.0-14; P = 0.477). The degree of association between the serum E2 and the MSS, using the Spearman rank correlation coefficient, rs (95% CI) was small and not significant (-0.04, -0.34 to 0.26; P = 0.398). ROC curve analysis revealed an area under the curve (95% CI) of 0.51 (0.33-0.68). CONCLUSIONS: More than half the women were inadequately replaced to protect against osteoporosis. Furthermore, the MSS was of no value in screening for those with low serum E2 levels. Serum E2 levels should be monitored in women on HRT for osteoporosis prevention and the E2 dosage adjusted accordingly.

Full Text

The Full Text of this article is available as a PDF (60.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adami S., Suppi R., Bertoldo F., Rossini M., Residori M., Maresca V., Lo Cascio V. Transdermal estradiol in the treatment of postmenopausal bone loss. Bone Miner. 1989 Aug;7(1):79–86. doi: 10.1016/0169-6009(89)90064-0. [DOI] [PubMed] [Google Scholar]
  2. Barlow D. H., Abdalla H. I., Roberts A. D., Al Azzawi F., Leggate I., Hart D. M. Long-term hormone implant therapy--hormonal and clinical effects. Obstet Gynecol. 1986 Mar;67(3):321–325. [PubMed] [Google Scholar]
  3. Belchetz P. E. Hormonal treatment of postmenopausal women. N Engl J Med. 1994 Apr 14;330(15):1062–1071. doi: 10.1056/NEJM199404143301508. [DOI] [PubMed] [Google Scholar]
  4. Berner B., John V. A. Pharmacokinetic characterisation of transdermal delivery systems. Clin Pharmacokinet. 1994 Feb;26(2):121–134. doi: 10.2165/00003088-199426020-00005. [DOI] [PubMed] [Google Scholar]
  5. Brincat M., Magos A., Studd J. W., Cardozo L. D., O'Dowd T., Wardle P. J., Cooper D. Subcutaneous hormone implants for the control of climacteric symptoms. A prospective study. Lancet. 1984 Jan 7;1(8367):16–18. doi: 10.1016/s0140-6736(84)90183-1. [DOI] [PubMed] [Google Scholar]
  6. Diver M. J. Monitoring of hormone replacement therapy. Lancet. 1992 Dec 12;340(8833):1471–1471. doi: 10.1016/0140-6736(92)92661-x. [DOI] [PubMed] [Google Scholar]
  7. Diver M. J., Nisbet J. A. Warning on plasma oestradiol measurement. Lancet. 1987 Nov 7;2(8567):1097–1097. doi: 10.1016/s0140-6736(87)91534-0. [DOI] [PubMed] [Google Scholar]
  8. Ettinger B. Optimal use of postmenopausal hormone replacement. Obstet Gynecol. 1988 Nov;72(5 Suppl):31S–36S. [PubMed] [Google Scholar]
  9. Evans S. F., Davie M. W. Low and conventional dose transdermal oestradiol are equally effective at preventing bone loss in spine and femur at all post-menopausal ages. Clin Endocrinol (Oxf) 1996 Jan;44(1):79–84. doi: 10.1046/j.1365-2265.1996.637459.x. [DOI] [PubMed] [Google Scholar]
  10. Griffiths F., Convery B. Women's use of hormone replacement therapy for relief of menopausal symptoms, for prevention of osteoporosis, and after hysterectomy. Br J Gen Pract. 1995 Jul;45(396):355–358. [PMC free article] [PubMed] [Google Scholar]
  11. Hanley J. A., McNeil B. J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982 Apr;143(1):29–36. doi: 10.1148/radiology.143.1.7063747. [DOI] [PubMed] [Google Scholar]
  12. Hassager C., Christiansen C. Current techniques for bone mass measurement. Baillieres Clin Obstet Gynaecol. 1991 Dec;5(4):807–815. doi: 10.1016/s0950-3552(05)80288-3. [DOI] [PubMed] [Google Scholar]
  13. Henderson A. R. Assessing test accuracy and its clinical consequences: a primer for receiver operating characteristic curve analysis. Ann Clin Biochem. 1993 Nov;30(Pt 6):521–539. doi: 10.1177/000456329303000601. [DOI] [PubMed] [Google Scholar]
  14. Jones K. P. Estrogens and progestins: what to use and how to use it. Clin Obstet Gynecol. 1992 Dec;35(4):871–883. [PubMed] [Google Scholar]
  15. Lindsay R., Hart D. M., Clark D. M. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol. 1984 Jun;63(6):759–763. [PubMed] [Google Scholar]
  16. Morris A., Thomas S. A med/surg nursing record: convenient, adequate--and accepted. Nurs Manage. 1992 May;23(5):68-70, 72. doi: 10.1097/00006247-199205000-00018. [DOI] [PubMed] [Google Scholar]
  17. Naessén T., Persson I., Ljunghall S., Bergström R. Women with climacteric symptoms: a target group for prevention of rapid bone loss and osteoporosis. Osteoporos Int. 1992 Sep;2(5):225–231. doi: 10.1007/BF01624146. [DOI] [PubMed] [Google Scholar]
  18. Nisbet J. A., Jomain P. A. Discrepancies in plasma estradiol values obtained with commercial kits. Clin Chem. 1987 Sep;33(9):1672–1672. [PubMed] [Google Scholar]
  19. Padwick M. L., Endacott J., Whitehead M. I. Efficacy, acceptability, and metabolic effects of transdermal estradiol in the management of postmenopausal women. Am J Obstet Gynecol. 1985 Aug 15;152(8):1085–1091. doi: 10.1016/0002-9378(85)90567-8. [DOI] [PubMed] [Google Scholar]
  20. Powers M. S., Schenkel L., Darley P. E., Good W. R., Balestra J. C., Place V. A. Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17 beta-estradiol: comparison with conventional oral estrogens used for hormone replacement. Am J Obstet Gynecol. 1985 Aug 15;152(8):1099–1106. doi: 10.1016/0002-9378(85)90569-1. [DOI] [PubMed] [Google Scholar]
  21. Riggs B. L., Melton L. J., 3rd Involutional osteoporosis. N Engl J Med. 1986 Jun 26;314(26):1676–1686. doi: 10.1056/NEJM198606263142605. [DOI] [PubMed] [Google Scholar]
  22. Ryan P. J., Harrison R., Blake G. M., Fogelman I. Compliance with hormone replacement therapy (HRT) after screening for post menopausal osteoporosis. Br J Obstet Gynaecol. 1992 Apr;99(4):325–328. doi: 10.1111/j.1471-0528.1992.tb13732.x. [DOI] [PubMed] [Google Scholar]
  23. Savvas M., Studd J. W., Fogelman I., Dooley M., Montgomery J., Murby B. Skeletal effects of oral oestrogen compared with subcutaneous oestrogen and testosterone in postmenopausal women. BMJ. 1988 Jul 30;297(6644):331–333. doi: 10.1136/bmj.297.6644.331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Selby P. L., Peacock M. The effect of transdermal oestrogen on bone, calcium-regulating hormones and liver in postmenopausal women. Clin Endocrinol (Oxf) 1986 Nov;25(5):543–547. doi: 10.1111/j.1365-2265.1986.tb03607.x. [DOI] [PubMed] [Google Scholar]
  25. Steingold K. A., Laufer L., Chetkowski R. J., DeFazio J. D., Matt D. W., Meldrum D. R., Judd H. L. Treatment of hot flashes with transdermal estradiol administration. J Clin Endocrinol Metab. 1985 Oct;61(4):627–632. doi: 10.1210/jcem-61-4-627. [DOI] [PubMed] [Google Scholar]
  26. Stevenson J. C., Cust M. P., Gangar K. F., Hillard T. C., Lees B., Whitehead M. I. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet. 1990 Aug 4;336(8710):265–269. doi: 10.1016/0140-6736(90)91801-g. [DOI] [PubMed] [Google Scholar]
  27. Studd J., Savvas M., Waston N., Garnett T., Fogelman I., Cooper D. The relationship between plasma estradiol and the increase in bone density in postmenopausal women after treatment with subcutaneous hormone implants. Am J Obstet Gynecol. 1990 Nov;163(5 Pt 1):1474–1479. doi: 10.1016/0002-9378(90)90608-a. [DOI] [PubMed] [Google Scholar]
  28. Swets J. A. Measuring the accuracy of diagnostic systems. Science. 1988 Jun 3;240(4857):1285–1293. doi: 10.1126/science.3287615. [DOI] [PubMed] [Google Scholar]
  29. Thom M. H., Collins W. P., Studd J. W. Hormonal profiles in postmenopausal women after therapy with subcutaneous implants. Br J Obstet Gynaecol. 1981 Apr;88(4):426–433. doi: 10.1111/j.1471-0528.1981.tb01008.x. [DOI] [PubMed] [Google Scholar]
  30. Zweig M. H., Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993 Apr;39(4):561–577. [PubMed] [Google Scholar]

Articles from The British Journal of General Practice are provided here courtesy of Royal College of General Practitioners

RESOURCES